Troy Ignelzi bought $144K of Rapport Therapeutics stock
By AlphaYouPublished Form 4
Ignelzi Troy A.
Reporting filer
Troy Ignelzi reported buying 5,500 shares of Rapport Therapeutics, Inc. for about $144K ($26.10 a share on average). Form 4 filed Oct 21, 2026 lists 1 entry.
See the price move since this trade →
- Disclosed
- Oct 21, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Ignelzi Troy A. | 2026-10-21 | P | Purchase | 5500 | 26.10 | 15,500 | 0 days | Filed terms
|
Common Stock
- Owner
- Ignelzi Troy A.
- Date
- 2026-10-21
- Code
- P
- Action
- Purchase
- Quantity
- 5500
- Price
- 26.10
- Following holdings
- 15,500
- Reporting delay
- 0 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-21
- transaction Form Type: 4
- transaction Code: P
- equity Swap Involved: false
- transaction Shares: 5500
- transaction Price Per Share: 26.10
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 15500
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Ignelzi Troy A.: Chief Financial Officer.
Original sources
Prepared automatically from public filing data. Report a correction.